News

Innovative Health Initiative - Draft topics for Calls 6 & 7 published

Published on | 2 years ago

Programmes Health

The Innovative Health Initiative (IHI) has published the draft texts of topics under consideration for inclusion in the next calls for proposals on the Future Opportunities page of the website. Currently, the draft topics are under consultation and it is therefore likely that the topics may change considerably between now and the call launch, and applicants should check the final, approved topic texts once the calls are launched.

Herewith an overview of the draft topics:

IHI call 6

Call type: two stage

  • Support healthcare system resilience through a focus on persistency in the treatment of chronic diseases
  • Development of practical guidelines and recommendations for using real world data/real world evidence in healthcare decision making


IHI call 7

Call type: single stage

  • Improving clinical management of heart disease from early detection to treament
  • User-centric technologies and optimised hospital workflow for a sustainable healthcare workforce
  • Clinical validation of biomarkers for diagnosis, monitoring disease progression and treatment response


More information on IHI's website

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1743 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.